BRPI0510290B8 - Partícula ou agregado nanoparticulado compósito biocompatível, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partículas ou agregados nanoparticulados ou de uma composição - Google Patents

Partícula ou agregado nanoparticulado compósito biocompatível, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partículas ou agregados nanoparticulados ou de uma composição

Info

Publication number
BRPI0510290B8
BRPI0510290B8 BRPI0510290A BRPI0510290A BRPI0510290B8 BR PI0510290 B8 BRPI0510290 B8 BR PI0510290B8 BR PI0510290 A BRPI0510290 A BR PI0510290A BR PI0510290 A BRPI0510290 A BR PI0510290A BR PI0510290 B8 BRPI0510290 B8 BR PI0510290B8
Authority
BR
Brazil
Prior art keywords
particles
composition
nanoparticulate
pharmaceutical
aggregates
Prior art date
Application number
BRPI0510290A
Other languages
English (en)
Inventor
Kader Boussaha Abdel
Jim Bergey Earl
André Panak Edouard
François Hochepied Jean
Jérémy Balencie
Laurent Levy
Nath Prasad Paras
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of BRPI0510290A publication Critical patent/BRPI0510290A/pt
Publication of BRPI0510290A8 publication Critical patent/BRPI0510290A8/pt
Publication of BRPI0510290B1 publication Critical patent/BRPI0510290B1/pt
Publication of BRPI0510290B8 publication Critical patent/BRPI0510290B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

partícula ou agregado nanoparticulado compósito biocompatível, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partículas ou agregados nanoparticulados ou de uma composição. a presente invenção refere-se a novas partículas ativáveis utilizáveis no domínio da saúde. ela refere-se notadamente a partículas compósitas capazes de gerar radicais livres ou no calor sob excitação dos raios x, e suas utilizações em saúde, notadamente humana. as partículas da invenção compreendem um núcleo à base de compostos inorgânicos e, eventualmente, orgânicos, e elas podem ser ativadas in vivo, para marcar ou alterar células, tecidos ou órgãos. a invenção refere-se igualmente a processos de produção de tais partículas, assim como de composições farmacêuticas ou diagnósticos que as contenham.
BRPI0510290A 2004-05-10 2005-05-09 Partícula ou agregado nanoparticulado compósito biocompatível, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partículas ou agregados nanoparticulados ou de uma composição BRPI0510290B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0405036 2004-05-10
FR0405036A FR2869803B1 (fr) 2004-05-10 2004-05-10 Particules activables, preparation et utilisations
PCT/FR2005/001145 WO2005120590A1 (fr) 2004-05-10 2005-05-09 Particules activables, preparation et utilisations

Publications (4)

Publication Number Publication Date
BRPI0510290A BRPI0510290A (pt) 2007-10-30
BRPI0510290A8 BRPI0510290A8 (pt) 2019-01-02
BRPI0510290B1 BRPI0510290B1 (pt) 2021-06-01
BRPI0510290B8 true BRPI0510290B8 (pt) 2021-10-19

Family

ID=34945762

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510290A BRPI0510290B8 (pt) 2004-05-10 2005-05-09 Partícula ou agregado nanoparticulado compósito biocompatível, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partículas ou agregados nanoparticulados ou de uma composição

Country Status (24)

Country Link
US (2) US9162079B2 (pt)
EP (1) EP1744789B1 (pt)
JP (1) JP5150251B2 (pt)
KR (2) KR101234334B1 (pt)
CN (1) CN100592921C (pt)
AT (1) ATE403444T1 (pt)
AU (1) AU2005251499B2 (pt)
BR (1) BRPI0510290B8 (pt)
CA (1) CA2564197C (pt)
CY (1) CY1108369T1 (pt)
DE (1) DE602005008731D1 (pt)
DK (1) DK1744789T3 (pt)
EA (1) EA010246B1 (pt)
ES (1) ES2312004T3 (pt)
FR (1) FR2869803B1 (pt)
HR (1) HRP20080534T3 (pt)
IL (1) IL178877A (pt)
MX (1) MXPA06013095A (pt)
PL (1) PL1744789T3 (pt)
PT (1) PT1744789E (pt)
RS (1) RS50615B (pt)
SI (1) SI1744789T1 (pt)
WO (1) WO2005120590A1 (pt)
ZA (1) ZA200610255B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2867180B1 (fr) 2004-03-02 2006-06-16 Univ Claude Bernard Lyon Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
FR2877571B1 (fr) * 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
CA2587392C (en) * 2004-11-15 2013-02-12 Australian Nuclear Science & Technology Organisation Solid particles from controlled destabilisation of microemulsions
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
EP1852107A1 (en) * 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
EP1920784A1 (en) * 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging
US9358292B2 (en) 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
US8376013B2 (en) 2008-03-11 2013-02-19 Duke University Plasmonic assisted systems and methods for interior energy-activation from an exterior source
US9488916B2 (en) 2007-04-08 2016-11-08 Immunolight, Llc. Interior energy-activation of photo-reactive species inside a medium or body
US8951561B2 (en) 2007-08-06 2015-02-10 Duke University Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP)
FR2922106B1 (fr) * 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
US20090104113A1 (en) * 2007-10-18 2009-04-23 Searete Llc Ionizing-radiation-responsive compositions, methods, and systems
US8529426B2 (en) * 2007-10-18 2013-09-10 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US8168958B2 (en) * 2007-10-18 2012-05-01 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
GB2453860B (en) * 2007-10-18 2011-03-16 Searete Llc Ionizing-radiation-responsive compositions,methods and systems
US8227204B2 (en) * 2007-10-18 2012-07-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8164074B2 (en) * 2007-10-18 2012-04-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8684898B2 (en) * 2007-10-18 2014-04-01 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US9557635B2 (en) * 2007-10-18 2017-01-31 Gearbox, Llc Ionizing-radiation-responsive compositions, methods, and systems
US9907976B2 (en) * 2011-07-08 2018-03-06 Immunolight, Llc Phosphors and scintillators for light stimulation within a medium
EP2268311A4 (en) 2008-04-04 2014-08-27 Immunolight Llc NON-INVASIVE SYSTEMS AND IN SITU PHOTOBIOMODULATION METHODS
EP2130553A1 (en) * 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US8770203B2 (en) 2008-07-14 2014-07-08 Immunolight, Llc. Advanced methods and systems for treating cell proliferation disorders
CN102231991A (zh) 2008-07-31 2011-11-02 生物工程大学精神物质实验室 应用于生物分析的活性粒子及其制备方法
TWI511756B (zh) 2009-04-21 2015-12-11 伊穆諾萊特公司 用以修飾介導生物活性或與生物活性有關之標靶結構之醫藥組合物或套組
WO2011060033A1 (en) 2009-11-10 2011-05-19 Immunolight, L.L.C. Up and down coversion systems for production of emitted light from various energy sources including radio frequency, microwave energy and magnetic induction sources for upconversion
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
EP2567257B1 (en) 2010-05-06 2021-03-24 Immunolight, Llc. Adhesive bonding composition and method of use
AU2011293132C1 (en) 2010-08-27 2016-04-21 Sebacia, Inc. Compositions and methods for targeted thermomodulation
US9572880B2 (en) 2010-08-27 2017-02-21 Sienna Biopharmaceuticals, Inc. Ultrasound delivery of nanoparticles
US9116246B2 (en) * 2011-04-07 2015-08-25 Stc.Unm Thermal neutron detectors based on gadolinium-containing nanoscintillators
JPWO2012153820A1 (ja) * 2011-05-12 2014-07-31 コニカミノルタ株式会社 Ｘ線吸収蛍光ナノ粒子
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
WO2013035739A1 (ja) * 2011-09-05 2013-03-14 株式会社Ihi 温熱治療用材料、温熱治療用システム及び温熱治療方法
BR112014014412A2 (pt) 2011-12-16 2017-06-13 Nanobiotix nanopartículas compreendendo materiais metálicos e de óxido de háfnio, sua preparação e uso
CA2887687A1 (en) 2012-10-11 2014-04-17 Nanocomposix, Inc. Silver nanoplate compositions and methods
JP6484229B2 (ja) * 2013-06-20 2019-03-13 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 腫瘍学に使用するための組成物および方法
BR112015031977A2 (pt) * 2013-06-20 2017-07-25 Nanobiotix gel biocompatível, e, kit
FR3018451A1 (fr) * 2014-03-13 2015-09-18 Chromalys Nanoparticules pour leur utilisation dans la detection de tumeurs mobiles
WO2015149188A1 (en) * 2014-04-03 2015-10-08 The Governing Council Of The University Of Toronto Multifunctional nanoparticle compositions and uses thereof
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
EP3206987B2 (en) 2014-10-14 2024-07-24 The University of Chicago Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
US20180008733A1 (en) * 2015-01-08 2018-01-11 Purdue Research Foundation Non-toxic formulations of radio-luminescent nanoparticles for use as cancer radio-sensitizing agents
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
US9770688B2 (en) * 2015-10-22 2017-09-26 King Fahd University Of Petroleum And Minerals Si—Y nanocomposite membrane and methods of making and use thereof
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
AU2017371069C1 (en) 2016-12-08 2025-02-27 Centre National De La Recherche Scientifique Bismuth-gadolinium nanoparticles
US10283476B2 (en) 2017-03-15 2019-05-07 Immunolight, Llc. Adhesive bonding composition and electronic components prepared from the same
EP3638367A4 (en) 2017-08-02 2021-07-21 The University of Chicago NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE
EP3849613A2 (en) 2018-06-01 2021-07-21 Tae Life Sciences Biodegradable nanocarriers for neutron capture therapy and methods thereof
US20240000940A1 (en) * 2020-12-01 2024-01-04 Nanobiotix S.A. Porous, high-z and carbon-free particles as radioenhancers
CN112655715A (zh) * 2020-12-25 2021-04-16 杭州甜蜜按钮科技有限公司 一种哺乳期羊舍专用消毒剂的制备方法
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
EP4595983A1 (en) 2024-02-05 2025-08-06 BXTA Nanotherapy Limited Nanoparticles functionalised with a stabilising agent and a targeting agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985173A (en) * 1997-11-18 1999-11-16 Gray; Henry F. Phosphors having a semiconductor host surrounded by a shell
JP3490015B2 (ja) * 1999-03-11 2004-01-26 関西ティー・エル・オー株式会社 化学的耐久性に優れた放射性微小球及びその製造方法
WO2001058458A1 (en) * 2000-02-08 2001-08-16 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
DE50109214D1 (de) * 2000-05-05 2006-05-11 Bayer Technology Services Gmbh Dotierte nanoteilchen als biolabel
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
CN1336174A (zh) * 2001-08-27 2002-02-20 董国臣 X线激发氧化锌卟啉化合物光动力作用的组合物抗癌光弹
JP2007514736A (ja) * 2003-12-17 2007-06-07 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 紫外線放射ナノ粒子を用いた放射線治療および医学画像
US8128908B2 (en) * 2004-04-30 2012-03-06 University Of Florida Research Foundation, Inc. Nanoparticles and their use for multifunctional bioimaging
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same

Also Published As

Publication number Publication date
KR20070014172A (ko) 2007-01-31
EP1744789A1 (fr) 2007-01-24
US9162079B2 (en) 2015-10-20
WO2005120590A1 (fr) 2005-12-22
IL178877A0 (en) 2007-03-08
RS50615B (sr) 2010-06-30
IL178877A (en) 2010-12-30
JP5150251B2 (ja) 2013-02-20
FR2869803B1 (fr) 2006-07-28
JP2007536356A (ja) 2007-12-13
EA200602077A1 (ru) 2007-04-27
BRPI0510290B1 (pt) 2021-06-01
DE602005008731D1 (de) 2008-09-18
US9433800B2 (en) 2016-09-06
CA2564197A1 (fr) 2005-12-22
ZA200610255B (en) 2008-09-25
EA010246B1 (ru) 2008-06-30
KR20120123731A (ko) 2012-11-09
HK1099508A1 (zh) 2007-08-17
BRPI0510290A (pt) 2007-10-30
US20070217996A1 (en) 2007-09-20
PT1744789E (pt) 2008-11-04
US20150238775A1 (en) 2015-08-27
CY1108369T1 (el) 2014-02-12
ES2312004T3 (es) 2009-02-16
HRP20080534T3 (en) 2008-11-30
ATE403444T1 (de) 2008-08-15
AU2005251499B2 (en) 2010-06-10
CA2564197C (fr) 2013-05-07
SI1744789T1 (sl) 2008-10-31
CN1950111A (zh) 2007-04-18
CN100592921C (zh) 2010-03-03
MXPA06013095A (es) 2007-04-27
EP1744789B1 (fr) 2008-08-06
FR2869803A1 (fr) 2005-11-11
AU2005251499A1 (en) 2005-12-22
BRPI0510290A8 (pt) 2019-01-02
DK1744789T3 (da) 2008-12-08
PL1744789T3 (pl) 2009-01-30
KR101234334B1 (ko) 2013-02-18

Similar Documents

Publication Publication Date Title
BRPI0510290B8 (pt) Partícula ou agregado nanoparticulado compósito biocompatível, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partículas ou agregados nanoparticulados ou de uma composição
Timofejeva et al. Calcium phosphate/polyvinyl alcohol composite hydrogels: A review on the freeze-thawing synthesis approach and applications in regenerative medicine
ATE530168T1 (de) Magnetische nanoteilchen-zusammensetzungen und ihre verwendungen
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
BRPI0908686B8 (pt) método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
BR0309167A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação
BRPI0610321B8 (pt) imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica
BR122019025997B8 (pt) uso de uma população de nanopartículas metálicas
MX367131B (es) Sales de xantilio 3,6-disustituidas.
BR112015031977A2 (pt) gel biocompatível, e, kit
Wang et al. Photocrosslinked gelatin methacryloyl/hyaluronic acid methacryloyl composite hydrogels loaded with bone morphogenetic protein 2-black phosphorus nanosheets for bone regeneration
BR112015031984A2 (pt) gel biocompatível compreendendo nanopartículas e/ou agregados de nanopartículas; e kit compreendendo um gel biocompatível
BR112012006267A2 (pt) processo para produzir partículas de substrato orgânico ligadas a nanopartículas ferromagnéticas comutáveis, partículas de substrato para diagnóstico, uso de nanopartículas ferromagnéticas comutáveis, e, medicamento para o tratamento de hipertermia no corpo humano ou animal
Ellis Nanodentistry: The benefits of nanotechnology in dentistry and its impact on oral health
BRPI0406844A (pt) Derivados de carboxamida e seu uso como inibidores do fator xa
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
SRINIVASAN et al. Synthesis and Assessment of the Antimicrobial Efficacy of a Novel Graphene Oxide-Copper Oxide Nanocomposite Against Oral Pathogens: An In-vitro Study.
Yeh et al. Poly-ε-caprolactone/multi-wall carbon nanotube composites as osteoinductive scaffolds for alveolar bone regeneration
Toulou Extrusion-Based 3D-Printed Quercetin Loaded Polycaprolactone–Tricalcium Phosphate Scaffold for Bone Tissue Engineering Applications
Sales Fabrico e caracterização mecânica de placas estabilizadoras de fraturas em material compósito polimérico
BRPI0514181A (pt) compostos orgánicos
Pei et al. Global Landscape Of Bone Tumor Therapy And Biomaterials: A Bibliometric And Citespace Analysis.
Laviv et al. Island Osteoperiosteal Flap Vitality when Isolated from Basal Bone by Silicone Interposition: An Experimental Study in Rabbit Tibia.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/05/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI NO 2626 DE 04/05/2021.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2630, QUANTO AO RELATORIO DESCRITIVO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2722 DE 07-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.